Lymphoid chemokines, including CCL19, CCL21 and CXCL13, are critical in the development and organization of secondary lymphoid tissues and in the generation of adaptive immune responses. These molecules have also been implicated in the development of ectopic lymphoid structures in the setting of chronic inflammation. Here we review current knowledge on the production of lymphoid chemokines in the central nervous system during both homeostatic conditions and in disease states. Accumulating evidence suggests that constitutive expression of CCL19 plays a critical immunosurveillance role in healthy individuals. In contrast, aberrant induction of CCL19, CCL21 and CXCL13 may support the establishment of chronic autoimmunity and hematopoetic tumors within the CNS.
Introduction
The lymphoid chemokines, CCL19, CCL21 and CXCL13, constitute a subclass of chemoattractant molecules originally identified based on their roles in the development and maintenance of secondary lymphoid tissues. These chemokines are constitutively expressed in lymph nodes, spleen and Peyer's patches. They regulate the homing of lymphocytes and myeloid cells to spatially segregated compartments within secondary lymphoid tissues, thereby facilitating cognate antigen-specific interactions and the generation of adaptive immune responses (Yoshie et al., 1997; Zlotnik et al., 1999; Mantovani, 1999) .
CCL19 and CCL21 are produced by stromal cells in the T cell zones of lymph nodes and spleen. CCL21 is also expressed in high endothelial venules (HEVs) and lymphatic vessels (Cyster, 1999) . Both of these chemokines bind to CCR7, which is expressed on the surface of naive T cells and mature dendritic cells (DC). CCL21 also binds CXCR3 with lower affinity. CXCL13 is produced by follicular DC within B cell follicles and binds to the receptor, CXCR5. It drives the migration of B cells and CD4 + helper T cells (follicular Th cells) to B cell rich areas (Förster et al., 1996; Legler et al., 1998; Ansel et al., 1999; Moser et al., 2002; Müller and Lipp, 2003) . Hence, CCL19 and CCL21 expedite antigen-specific CD4 + T cell immunity, while CXCL13 is critical for normal germinal center formation as well as for efficient immunoglobulin cross-switching and affinity maturation (Junt et al., 2005) .
In addition to their role in the development and maintenance of secondary lymphoid tissues, CCL19, CCL21 and CXCL13 can be induced in non-lymphoid tissues during chronic inflammation. In this setting they have been implicated in the process of lymphoid neogenesisthe organization of infiltrating immune cells and stromal elements into structured aggregates that recapitulate many of the features of secondary lymphoid tissues (Hjelmström, 2001) . When formed in response to persistent infection, these ectopic lymphoid structures have been shown to contain the spread of microbes (Halle et al., 2009; Moyron-Quiroz et al., 2004) . However, lymphoid neogenesis also has the potential to aggravate autoimmune inflammation via the recruitment and activation of autoantigen-specific T and B lymphocytes within the target organ (Aloisi and Pujol-Borrell, 2006) . Ectopic lymphoid follicles have been found in the salivary glands in Sjogren's syndrome (Salomonsson et al., 2002) , the synovium in rheumatoid arthritis (Takemura et al., 2001 ) and the thyroid gland in Hashimoto's thyroiditis (Hjelmström, 2001 ).
Here, we will review the literature concerning the production of lymphoid chemokines in the central nervous system (CNS), both during homeostasis and in disease states. In certain circumstances, CNS lymphoid chemokines act to the benefit of the host. For example, there is growing evidence that constitutive expression of CCL19 and CCL21 in cerebrovascular endothelium and the choroid plexus plays a critical role in immune surveillance of the subarachnoid and perivascular spaces of healthy individuals. In addition, induction of lymphoid chemokines in CNS tissues might participate in the clearance of local infections, such as neuroborreliosis and Toxoplasmosis gondii. Conversely, aberrant production of CCL19, CCL21 and CXCL13 may support the establishment of hematopoetic tumors or chronic autoimmunity in the brain and spinal cord (Fig. 1) . Journal of Neuroimmunology 224 (2010) 56-61 
